The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
are there people that are actually looking at a pure Pharma strategy where they're making an IND and going down the drug pathway absolutely absolutely there there are pharmaceutical drug uh actually they're all startups so um but pharmaceutical drug companies that are using the microbiome to as as the therapeutic and filing inds and um you know doing these studies
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.